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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To compare the benefits and harms of different treatments of hepatorenal syndrome in people with decompensated liver cirrhosis.
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B A C K G R O U N D
Description of the condition
Liver cirrhosis
The liver is a complex organ with multiple functions including
carbohydrate metabolism, fat metabolism, protein metabolism,
drug metabolism, synthetic functions, storage functions, digestive
functions, excretory functions, and immunological functions (Read
1972). Liver cirrhosis is a liver disease in which the normal micro-
circulation, the gross vascular anatomy, and the hepatic architec-
ture have been variably destroyed and altered with fibrous sep-
ta surrounding regenerated or regenerating parenchymal nodules
(Tsochatzis 2014; NCBI 2018). The major causes of liver cirrhosis
include excessive alcohol consumption, viral hepatitis, non-alco-
hol related fatty liver disease, autoimmune liver disease, and meta-
bolic liver disease (Williams 2014; Ratib 2015; Setiawan 2016). The
global prevalence of liver cirrhosis is difficult to estimate as most
estimates correspond to chronic liver disease (which includes liver
fibrosis and liver cirrhosis). In studies from the USA, the prevalence
of chronic liver disease varies between 0.3% to 2.1% (Scaglione
2015; Setiawan 2016); in the UK, the prevalence was 0.1% in one
study (Fleming 2008). In 2010, liver cirrhosis was responsible for an
estimated 2% of all global deaths, equivalent to 1 million deaths
(Mokdad 2014). There is an increasing trend of cirrhosis-related
deaths in some countries like the UK, while there is a decreasing
trend in other countries like France (Mokdad 2014; Williams 2014).
The major cause of complications and deaths in people with liver
cirrhosis is due to the development of clinically significant portal
hypertension (hepatic venous pressure gradient at least 10 mmHg)
(de Franchis 2015). Some of the clinical features of decompensa-
tion include jaundice, coagulopathy, ascites, variceal bleeding, he-
patic encephalopathy, and renal failure (de Franchis 2015; McPher-
son 2016; EASL 2018). Decompensated cirrhosis is the most com-
mon indication for liver transplantation (Merion 2010; Adam 2012).
Hepatorenal syndrome
Hepatorenal syndrome is renal failure in people with cirrhosis in
the absence of other causes of renal failure such as nephrotoxic
drugs and underlying renal pathology (Angeli 2015). The current
criteria for the diagnosis of hepatorenal syndrome are provided in
Table 1 (Angeli 2015). Hepatorenal syndrome can be classified into
type I and type II hepatorenal syndrome. Type I hepatorenal syn-
drome has a rapidly progressive reduction in renal function, while
type II hepatorenal syndrome does not follow a rapidly progressive
course (Arroyo 1996). Type I hepatorenal syndrome is associated
with acute kidney injury, while type II hepatorenal syndrome is as-
sociated with chronic kidney disease (Wong 2011). However, the
most recent diagnostic criteria of hepatorenal syndrome include
acute kidney injury (Angeli 2015), that is most individuals classified
as having hepatorenal syndrome per the current definition will fall
under the type I hepatorenal syndrome of past definitions. Approx-
imately 10% of patients hospitalised for other complications of cir-
rhosis develop hepatorenal syndrome (Dong 2016). Approximately
30% to 60% of people hospitalised for hepatorenal syndrome die
within a year (Israelsen 2017). The annual direct medical costs of
treatment of hepatorenal syndrome range between approximately
USD 3 billion (3,000 million) and USD 3.8 billion (3,800 million) (Rice
2017).
Pathophysiology of hepatorenal syndrome
Portal hypertension causes arterial vasodilatation of the splanch-
nic circulation (dilation of the blood vessels supplying the diges-
tive organs in the abdomen such as liver, pancreas, and intestines)
(Gines 2009). This decreases the intravascular volume. In the ear-
ly stages of portal hypertension, the body maintains arterial blood
pressure by increasing the cardiac output; however, in later stages
of portal hypertension, the increase in cardiac output is not suf-
ficient to ensure sufficient blood supply to vital organs, and the
body maintains arterial blood pressure by the activation of vaso-
constrictor mechanisms (Gines 2009). These vasoconstrictor mech-
anisms include the renin–angiotensin system, the sympathetic ner-
vous system, and non-osmotic hypersecretion of antidiuretic hor-
mone (Gines 2009), and lead to decreased blood flow to the kidneys
by renal arterial vasoconstriction, and eventually to renal failure
(Gines 2009).
Description of the intervention
Development of hepatorenal syndrome is considered one of the
manifestations of end-stage liver disease, which is one of the indi-
cations for liver transplantation (EASL 2016). Liver transplantation
is considered the definitive treatment for hepatorenal syndrome in
people who can undergo liver transplantation (Gines 2009; Aceve-
do 2017; EASL 2018). Supportive measures like treatment of the
precipitating cause of renal failure, such as infections or gastroin-
testinal bleeding and fluid overload, should be provided to peo-
ple during waiting time for liver transplantation and to people who
cannot undergo liver transplantation due to contraindications (e.g.
metastatic liver disease) (Gines 2009; EASL 2016). In addition, treat-
ment of hepatorenal syndrome in the form of systemic vasocon-
strictor drugs such as vasopressin analogues or noradrenaline, as
well as renal vasodilator drugs such as dopamine, albumin, tran-
sjugular intrahepatic portosystemic shunt (TIPS), liver support with
molecular adsorbent recirculating system (MARS), and renal re-
placement therapy in the form of haemodialysis or haemofiltration
have been used while waiting for liver transplantation or in people
in whom transplantation cannot be performed (Gines 2009; Hino-
josa-Azaola 2014; Acevedo 2017; Allegretti 2017; EASL 2018).
How the intervention might work
Systemic vasoconstrictor drugs decrease the systemic vasodila-
tion, which is one of the mechanisms of developing hepatorenal
syndrome. Renal vasodilator drugs decrease the renal vasocon-
striction, which is one of the mechanisms of developing hepatore-
nal syndrome. Decreased intravascular volume is one of the mecha-
nisms of developing hepatorenal syndrome; albumin may increase
the intravascular oncotic pressure and prevent third-space loss, re-
sulting in maintenance of the intravascular volume (Caironi 2009).
Transjugular intrahepatic portosystemic shunt results in a reduc-
tion of portal hypertension, which is one of the mechanisms of de-
veloping hepatorenal syndrome. Liver support with MARS and re-
nal replacement therapy can be considered as bridging measures
to prevent further deterioration of patients until the time of liver
transplantation, or recovery from the precipitating factors (e.g. in-
fections or gastrointestinal bleeding).
Why it is important to do this review
It is important to provide optimal treatment to people with hepa-
torenal syndrome to improve their clinical outcomes while wait-
ing for liver transplantation or potentially prevent the need for
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transplantation, or both. This is particularly important given the
shortage of donor organs. Several different treatments are avail-
able; however, their relative efficacy and optimal combination are
not known. There have been two Cochrane Reviews on hepatore-
nal syndrome treatment (Allegretti 2017; Israelsen 2017); however,
there have been no previous network meta-analyses on the topic.
Network meta-analysis allows for a combination of direct and indi-
rect evidence and the ranking of different interventions for differ-
ent outcomes (Salanti 2011; Salanti 2012). With this systematic re-
view and network meta-analysis, we aim to provide the best level
of evidence for the benefits and harms of different treatments for
hepatorenal syndrome in people with decompensated liver cirrho-
sis. If it is not possible to perform this review with network meta-
analysis methods, we will instead use standard Cochrane methods
to perform head-to-head comparison meta-analysis whenever pos-
sible. We will also present results from direct comparisons whenev-
er possible, even if we perform the network meta-analysis.
O B J E C T I V E S
To compare the benefits and harms of different treatments of he-
patorenal syndrome in people with decompensated liver cirrhosis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will only consider randomised clinical trials for this network
meta-analysis irrespective of language, publication status, or date
of publication. We will exclude studies of other designs due to the
risk of bias in such studies. Inclusion of indirect observational evi-
dence could weaken our network meta-analysis, but this could al-
so be viewed as a strength for assessing rare adverse events. It is
well established that exclusion of non-randomised studies increas-
es the focus on potential benefits and reduces the focus on the risks
of serious adverse events and those of any adverse events. Howev-
er, due to the exponentially increased amount of work required for
non-randomised studies, we will register and perform a new sys-
tematic review and meta-analysis of non-randomised studies for
adverse events if there is uncertainty in the balance of benefits and
harms of effective treatment(s).
Types of participants
We will include randomised clinical trials with adult trial partic-
ipants undergoing treatment for hepatorenal syndrome with de-
compensated liver cirrhosis. We will exclude randomised clinical
trials in which participants had previously undergone liver trans-
plantation.
Types of interventions
We will include any of the following interventions for comparison
with one another, either alone or in combination.
• Noradrenaline (systemic vasoconstrictor)• Terlipressin (systemic vasoconstrictor)• Midodrine (systemic vasoconstrictor)• Dopamine (renal vasodilator)• Prostaglandins (renal vasodilator)• Albumin (maintain intravascular volume)• TIPS procedure (decrease portal hypertension)
• Other forms of portosystemic shunt (decrease portal hyperten-
sion)• Haemodialysis (renal replacement therapy)• Haemofiltration (renal replacement therapy)• MARS (liver support)• No active intervention (no intervention or placebo)
The above list is not exhaustive. If we identify treatments of which
we were unaware, we will consider eligibility of the treatments for
inclusion in the network if they are used primarily for treatment of
hepatorenal syndrome. We will report the findings for these inter-
ventions in the 'Results' and 'Discussion' sections of the review.
We will evaluate the plausibility of transitivity assumption by look-
ing at the inclusion and exclusion criteria in the studies. Transitivi-
ty assumption is the assumption that participants included in the
different trials with different treatments for hepatorenal syndrome
can be considered to be a part of a multi-arm randomised clini-
cal trial and could potentially have been randomised to any of the
interventions (Salanti 2012). In other words, any participant that
meets the inclusion criteria is, in principle, equally likely to be ran-
domised to any of the above eligible interventions. This necessi-
tates that information on potential effect-modifiers such as type of
hepatorenal syndrome (type I or type II) and the co-interventions
(use of prophylactic antibiotics) are the same across trials.
Types of outcome measures
Primary outcomes• All-cause mortality at maximal follow-up (time to death).• Health-related quality of life using a validated scale such as the
EQ-5D or 36-Item Short Form Health Survey (SF-36) at maximal
follow-up (EuroQol 2018; Optum 2018).• Serious adverse events (during or within six months after cessa-
tion of intervention). We define a serious adverse event as any
event that would increase mortality; is life-threatening; requires
hospitalisation; results in persistent or significant disability; is
a congenital anomaly/birth defect; or any important medical
event that might jeopardise the person or require intervention
to prevent it (ICH-GCP 1997). However, we will use the defini-
tions used by the study authors for serious adverse events.* Proportion of people with one or more serious adverse
events.* Number of serious adverse events per participant.
Secondary outcomes• Any adverse events (during or within six months after cessation
of intervention). We define an adverse event as any untoward
medical occurrence not necessarily having a causal relationship
with the intervention but resulting in a dose reduction or discon-
tinuation of intervention (any time after commencement of in-
tervention) (ICH-GCP 1997). However, we will use the definition
used by the study authors for adverse events.* Proportion of people with one or more adverse events.* Number of any adverse events per participant.• Time to liver transplantation (maximal follow-up).• Time to recovery from hepatorenal syndrome (maximal fol-
low-up).* Symptomatic recovery.* Recovery as per definitions used for hepatorenal syndrome.
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• Time to other features of decompensation (maximal follow-up).
Exploratory outcomes• Length of hospital stay (all hospital admissions until maximal
follow-up).• Number of days of lost work (in people who work) (maximal fol-
low-up).• Treatment costs (including the cost of the treatment and any re-
sulting complications).
We have chosen outcomes based on their importance to patients in
a survey related to research priorities for people with liver diseases
(Gurusamy 2018); on feedback of the patient and public represen-
tative of this project; and on an online survey about the outcomes
promoted through Cochrane Consumer Network.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library, MEDLINE Ovid, Embase Ovid,
and Science Citation Index Expanded (Web of Science) from in-
ception to date of search for randomised clinical trials comparing
two or more of the above interventions, applying no language re-
strictions (Royle 2003). We will search for all possible comparisons
formed by the interventions of interest. To identify further ongo-
ing or completed trials, we will also search the US National Insti-
tutes of Health Ongoing Trials Register ClinicalTrials.gov (clinical-
trials.gov) and the World Health Organization International Clinical
Trials Registry Platform (WHO ICTRP) (apps.who.int/trialsearch/),
which searches various trial registers, including ISRCTN and Clini-
calTrials.gov. We will also search the European Medicines Agency
(EMA) (www.ema.europa.eu/ema/) and US Food and Drug Admin-
istration (FDA) (www.fda.gov) registries for randomised clinical tri-
als. The provisional search strategies are provided in Appendix 1.
Searching other resources
We will search the references of the identified trials and the existing
Cochrane Reviews on hepatorenal syndrome to identify additional
trials for inclusion.
Data collection and analysis
Selection of studies
Two review authors (KG and LB) will independently screen the titles
and abstracts of studies identified by the search for potential inclu-
sion in the review. We will seek full-text articles for any references
identified by at least one of the review authors as potentially rele-
vant and assess trials for inclusion based on the full-text articles. We
will provide a list of excluded references and the reasons for their
exclusion in the 'Characteristics of excluded studies' table. We will
also list any ongoing trials identified primarily through the search
of the clinical trial registers for further follow-up. Any discrepancies
will be resolved through discussion.
Data extraction and management
Two review authors (KG and LB) will independently extract the data
below in a pre-piloted Microsoft Excel-based data extraction form
(after translation of non-English articles).
• Outcome data (for each outcome and for each intervention
group whenever applicable):* number of participants randomised;* number of participants included for the analysis;* number of participants with events for binary outcomes,
mean and standard deviation for continuous outcomes,
number of events and the mean follow-up period for count
outcomes, and number of participants with events and the
mean follow-up period for time-to-event outcomes;* natural logarithm of hazard ratio and its standard error if this
was reported rather than the number of participants with
events and the mean follow-up period for time-to-event out-
comes;* definition of outcomes or scale used if appropriate.• Data on potential effect modifiers:* participant characteristics such as age, sex, definition and
type of hepatorenal syndrome (type I or type II), the aetiolo-
gy for cirrhosis, and the interval between diagnosis of hepa-
torenal syndrome and treatment;* details of the intervention and control (including dose, fre-
quency, and duration);* length of follow-up;* information related to 'Risk of bias' assessment (see Assess-
ment of risk of bias in included studies).• Other data:* year and language of publication;* country in which the participants were recruited;* year(s) in which the trial was conducted;* inclusion and exclusion criteria.
We will collect outcomes at maximum follow-up but also at short-
term (up to three months) and medium-term (more than three
months to five years) if this is available.
We will contact the trial authors in the case of unclear or missing
information. If there is any doubt as to whether trials shared the
same participants, completely or partially (by identifying common
authors and centres), we will attempt to contact the trial authors
to clarify whether the trial report was duplicated. Any differences in
opinion will be resolved through discussion.
Assessment of risk of bias in included studies
We will follow the guidance in the Cochrane Handbook for System-
atic Reviews of Interventions and that described in the Cochrane He-
pato-Biliary Group Module to assess the risk of bias in included tri-
als (Higgins 2011; Gluud 2018). Specifically, we will assess sources
of bias as defined below (Schulz 1995; Moher 1998; Kjaergard 2001;
Wood 2008; Savović 2012a; Savović 2012b; Lundh 2017; Savović
2018).
Allocation sequence generation• Low risk of bias: the study authors performed sequence gener-
ation using computer random number generation or a random
number table. Drawing lots, tossing a coin, shuffling cards, and
throwing dice are adequate if performed by an independent per-
son not otherwise involved in the study. In general, we will classi-
fy the risk of bias is low if the method used for allocation conceal-
ment suggested that it was extremely likely that the sequence
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was generated randomly (e.g. the use of an interactive voice re-
sponse system).• Unclear risk of bias: the study authors did not specify the
method of sequence generation.• High risk of bias: the sequence generation method was not ran-
dom.
Allocation concealment• Low risk of bias: the participant allocations could not have been
foreseen in advance of, or during, enrolment. A central and inde-
pendent randomisation unit controlled allocation. The investi-
gators were unaware of the allocation sequence (e.g. if the allo-
cation sequence was hidden in sequentially numbered, opaque,
and sealed envelopes).• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so that the intervention
allocations may have been foreseen before, or during, enrol-
ment.• High risk of bias: it is likely that the investigators who assigned
the participants knew the allocation sequence. We will exclude
such quasi-randomised studies.
Blinding of participants and personnel• Low risk of bias: any of the following: blinding of participants
and key study personnel ensured, and it was unlikely that the
blinding could have been broken; or rarely no blinding or incom-
plete blinding, but the review authors judged that the outcome
was not likely to be influenced by lack of blinding.• Unclear risk of bias: any of the following: insufficient information
to permit judgement of 'low risk' or 'high risk'; or the trial did not
address this outcome.• High risk of bias: any of the following: no blinding or incomplete
blinding, and the outcome was likely to be influenced by lack
of blinding; or blinding of key study participants and personnel
attempted, but likely that the blinding could have been broken,
and the outcome was likely to be influenced by lack of blinding.
Blinded outcome assessment• Low risk of bias: any of the following: blinding of outcome as-
sessment ensured, and unlikely that the blinding could have
been broken; or rarely no blinding of outcome assessment, but
the review authors judged that the outcome measurement was
not likely to be influenced by lack of blinding.• Unclear risk of bias: any of the following: insufficient information
to permit judgement of 'low risk' or 'high risk'; or the trial did not
address this outcome.• High risk of bias: any of the following: no blinding of outcome
assessment, and the outcome measurement was likely to be in-
fluenced by lack of blinding; or blinding of outcome assessment,
but likely that the blinding could have been broken, and the out-
come measurement was likely to be influenced by lack of blind-
ing.
Incomplete outcome data• Low risk of bias: missing data were unlikely to make treatment
effects depart from plausible values. The study used sufficient
methods, such as multiple imputation, to handle missing data.
• Unclear risk of bias: there was insufficient information to assess
whether missing data in combination with the method used to
handle missing data were likely to induce bias on the results.• High risk of bias: the results were likely to be biased due to miss-
ing data.
Selective outcome reporting• Low risk of bias: the trial reported the following predefined out-
comes: at least one of the outcomes related to the main rea-
son for treatment of people with hepatorenal syndrome, name-
ly, mortality or resolution of hepatorenal syndrome along with
adverse events. If the original trial protocol was available, the
outcomes should have been those called for in that protocol. If
the trial protocol was obtained from a trial registry (e.g. Clinical-
Trials.gov), the outcomes sought should have been those enu-
merated in the original protocol if the trial protocol was regis-
tered before or at the time that the trial was begun. If the tri-
al protocol was registered after the trial was begun, those out-
comes will not be considered to be reliable.• Unclear risk of bias: not all predefined, or clinically relevant and
reasonably expected, outcomes were reported fully, or it was
unclear whether data on these outcomes were recorded or not.• High risk of bias: one or more predefined or clinically relevant
and reasonably expected outcomes were not reported, despite
the fact that data on these outcomes should have been available
and even recorded.
For-profit bias• Low risk of bias: the trial appeared to be free of industry spon-
sorship or other type of for-profit support that could manipu-
late the trial design, conductance, or results of the trial (indus-
try-sponsored trials overestimate the efficacy by about 25%)
(Lundh 2017).• Unclear risk of bias: the trial may or may not have been free
of for-profit bias, as no information on clinical trial support or
sponsorship was provided.• High risk of bias: the trial was sponsored by industry or received
another type of for-profit support.
Other bias• Low risk of bias: the trial appeared to be free of other compo-
nents that could put it at risk of bias (e.g. inappropriate control
or dose or administration of control, baseline differences, early
stopping).• Unclear risk of bias: the trial may or may not have been free of
other components that could put it at risk of bias.• High risk of bias: there were other factors in the trial that could
put it at risk of bias (e.g. baseline differences, early stopping).
We will consider a trial to be at low risk of bias if we assess the trial
to be at low risk of bias across all listed 'Risk of bias' domains. Oth-
erwise, we will consider trials to be at high risk of bias. At the out-
come level, we will classify an outcome to be at low risk of bias if the
allocation sequence generation; allocation concealment; blinding
of participants, healthcare professionals, and outcome assessors;
incomplete outcome data; and selective outcome reporting (at the
outcome level) are at low risk of bias for objective and subjective
outcomes (Savović 2018).
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Measures of treatment e8ect
Relative treatment effects
For dichotomous variables (e.g. the proportion of participants with
serious adverse events or any adverse event), we will calculate
the odds ratio (OR) with 95% credible interval (CrI) (or Bayesian
confidence interval) (Severini 1993). For continuous variables (e.g.
health-related quality of life reported on the same scale), we will
calculate the mean difference (MD) with 95% Crl. We will use stan-
dardised mean difference (SMD) values with 95% Crl for health-re-
lated quality of life if the included trials used different scales. For
count outcomes (e.g. number of serious adverse events or number
of any adverse event), we will calculate the rate ratio (RaR) with 95%
Crl. For time-to-event data (e.g. all-cause mortality at maximal fol-
low-up), we will calculate hazard ratio (HR) with 95% Crl.
Relative ranking
We will estimate the ranking probabilities for all interventions of
being at each possible rank for each intervention. We will obtain the
surface under the cumulative ranking curve (SUCRA) (cumulative
probability), rankogram, and relative ranking table with CrI for the
ranking probabilities (Salanti 2011; Chaimani 2013).
Unit of analysis issues
The unit of analysis is the participant undergoing treatment for he-
patorenal syndrome according to the intervention group to which
the participant was randomly assigned.
Cluster randomised clinical trials
We will include cluster randomised clinical trials provided that the
effect estimate adjusted for cluster correlation is available. If this
is not available, we will include such trials if sufficient information
to calculate the design effect is available from the trial because this
will allow us to take clustering into account. We will also assess ad-
ditional domains of risk of bias for cluster randomised trials accord-
ing to guidance in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
Cross-over randomised clinical trials
If we identify any cross-over randomised clinical trials, we will in-
clude the outcomes after the period of first intervention because
the included treatments can have residual effects.
Trials with multiple intervention groups
We will collect data for all trial intervention groups that meet the
inclusion criteria. The codes we will use for analysis will account
for the correlation between the effect sizes from studies with more
than two groups.
Dealing with missing data
We will perform an intention-to-treat analysis whenever possible
(Newell 1992); otherwise, we will use the data available to us. This
may result in the use of 'per-protocol' analyses. Since these may
be biased, particularly if the data are not missing at random (e.g.
treatment was withdrawn due to adverse events, or duration of
treatment was shortened due to lack of response and such partic-
ipants were excluded from analysis), we will conduct best-worst-
case scenario analysis (good outcome in intervention group and
bad outcome in control group) and worst-best-case scenario analy-
sis (bad outcome in intervention group and good outcome in con-
trol group) as sensitivity analyses whenever possible for dichoto-
mous outcomes.
For continuous outcomes, we will impute the standard deviation
from P values according to guidance in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). If the data are
likely to be normally distributed, we will use the median for meta-
analysis when the mean is not available. If it is not possible to calcu-
late the standard deviation from the P value or the confidence inter-
vals, we will impute the standard deviation using the largest stan-
dard deviation in other trials for that outcome. This form of impu-
tation can decrease the weight of the study for calculation of mean
differences and may bias the effect estimate to no effect for calcu-
lation of standardised mean differences (Higgins 2011).
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity by care-
fully examining the characteristics and design of included trials. We
will assess the presence of clinical heterogeneity by comparing ef-
fect estimates (see Subgroup analysis and investigation of hetero-
geneity) in trial reports of different drug dosages, different types
of hepatorenal syndrome (type I and type II), different aetiologies
for cirrhosis (e.g. alcohol-related liver disease, viral liver diseases,
autoimmune liver disease), and based on the co-interventions (e.g.
both groups receive prophylactic antibiotics to decrease the risk of
subacute bacterial peritonitis). Different study designs and risk of
bias can contribute to methodological heterogeneity.
We will assess statistical heterogeneity by comparing the results
of the fixed-effect model meta-analysis and the random-effects
model meta-analysis, between-study standard deviation (Tau2 and
comparing this with values reported in study of the distribution of
between-study heterogeneity) (Turner 2012), and by calculating I2
using Stata/SE 14.2. If we identify substantial clinical, methodolog-
ical, or statistical heterogeneity, we will explore the heterogeneity
and address it in subgroup analysis (see Subgroup analysis and in-
vestigation of heterogeneity).
Assessment of transitivity across treatment comparisons
We will assess the transitivity assumption by comparing the distri-
bution of the potential effect modifiers (clinical: type of hepatore-
nal syndrome (type I versus type II); methodological: risk of bias,
year of randomisation, duration of follow-up) across the different
pairwise comparisons.
Assessment of reporting biases
For the network meta-analysis, we will perform a comparison-ad-
justed funnel plot. If there is no meaningful way in which to rank
these studies (i.e. there was no specific change in the risk of bias
in the studies, sample size, or the control group used over time),
we will judge the reporting bias by the completeness of the search
(Chaimani 2012).
Data synthesis
Methods for indirect and mixed comparisons
We will conduct network meta-analyses to compare multiple in-
terventions simultaneously for each of the primary and secondary
outcomes. Network meta-analysis combines direct evidence with-
in trials and indirect evidence across trials (Mills 2012). We will ob-
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tain a network plot to ensure that the trials are connected by in-
terventions using Stata/SE 14.2 (Chaimani 2013). We will exclude
any trials that are not connected to the network from the network
meta-analysis and report only the direct pairwise meta-analysis for
such comparisons. We will summarise the population and method-
ological characteristics of the trials included in the network meta-
analysis in a table based on pairwise comparisons. We will conduct
a Bayesian network meta-analysis using the Markov chain Monte
Carlo method in OpenBUGS 3.2.3 as per guidance from the Na-
tional Institute for Health and Care Excellence (NICE) Decision Sup-
port Unit (DSU) documents (Dias 2016). We will model the treat-
ment contrast (i.e. log odds ratio for binary outcomes, mean dif-
ference or standardised mean difference for continuous outcomes,
log rate ratio for count outcomes, and log hazard ratio for time-
to-event outcomes) for any two interventions ('functional parame-
ters') as a function of comparisons between each individual inter-
vention and the reference group ('basic parameters') using appro-
priate likelihood functions and links (Lu 2006). We will use binomi-
al likelihood and logit link for binary outcomes, Poisson likelihood
and log link for count outcomes, binomial likelihood and comple-
mentary log-log link for time-to-event outcomes (a semiparamet-
ric model which excludes censored individuals from the denomi-
nator of ‘at risk’ individuals at the point when they are censored),
and normal likelihood and identity link for continuous outcomes.
We will use the 'no active intervention' as the reference group. We
will perform a fixed-effect model and random-effects model for the
network meta-analysis. We will report both models for comparison
with the reference group in a forest plot. For each pairwise compar-
ison in a table, we will report the fixed-effect model if the two mod-
els report similar results; otherwise, we will report the more con-
servative model.
We will use a hierarchical Bayesian model using three different ini-
tial values, employing codes provided by NICE DSU (Dias 2016).
We will use a normal distribution with large variance (10,000) for
treatment effect priors (vague or flat priors). For the random-ef-
fects model, we will use a prior distributed uniformly (limits: 0 to
5) for between-trial standard deviation but will assume same be-
tween-trial standard deviation across treatment comparisons (Dias
2016). We will use a 'burn-in' of 10,000 simulations, check for con-
vergence (of effect estimates and between-study heterogeneity) vi-
sually (i.e. whether the values in different chains mix very well by
visualisation), and run the models for another 10,000 simulations
to obtain effect estimates. If we do not obtain convergence, we will
increase the number of simulations for the 'burn-in'. If we still do
not obtain convergence, we will use alternate initial values and pri-
ors employing methods suggested by van Valkenhoef 2012. We will
estimate the probability that each intervention ranks at one of the
possible positions using the NICE DSU codes (Dias 2016).
Assessment of inconsistency
We will assess inconsistency (statistical evidence of the violation of
transitivity assumption) by fitting both an inconsistency model and
a consistency model. We will use inconsistency models employed
in the NICE DSU manual, as we will use a common between-study
standard deviation (Dias 2014). In addition, we will use design-by-
treatment full interaction model and inconsistency factor (IF) plots
to assess inconsistency (Higgins 2012; Chaimani 2013). We will use
Stata/SE 14.2 to create IF plots. In the presence of inconsistency,
we will assess whether the inconsistency was due to clinical or
methodological heterogeneity by performing separate analyses for
each of the different subgroups mentioned in the Subgroup analy-
sis and investigation of heterogeneity section.
If there is evidence of inconsistency, we will identify areas in the
network where substantial inconsistency might be present in terms
of clinical and methodological diversities between trials and, when
appropriate, limit network meta-analysis to a more compatible
subset of trials.
Direct comparison
We will perform the direct comparisons using the same codes and
the same technical details.
Calculation of required information size and Trial Sequential
Analysis
For calculation of the required information size, see Appendix 2.
We will perform Trial Sequential Analysis for direct comparisons to
control the risk of random errors when at least two trials are includ-
ed for the comparison of other interventions versus no active in-
tervention ('control') for the outcomes all-cause mortality at maxi-
mal follow-up and health-related quality of life, the two outcomes
that determine whether the intervention should be given (Wetter-
slev 2008; Thorlund 2011; TSA 2011; Wetterslev 2017). For all-cause
mortality at maximal follow-up, we will use an alpha error as per
guidance of Jakobsen 2014 (i.e. 0.033), power of 90% (beta error
of 10%) (Castellini 2017), a relative risk reduction of 20%, the me-
dian control group proportion observed in the trials, and the het-
erogeneity observed in the meta-analysis using Stata/SE 14.2, em-
ploying methods suggested by Miladinovic 2013. For health-related
quality of life, a continuous outcome, we will use an alpha error as
per guidance of Jakobsen 2014 (i.e. 0.033), power of 90% (beta er-
ror of 10%) (Castellini 2017), a standardised mean difference of 0.2,
the median health-related quality of life in the control group in the
trials, and the heterogeneity observed in the meta-analysis.
Subgroup analysis and investigation of heterogeneity
We plan to assess the differences in the effect estimates between
the following subgroups and investigate heterogeneity and incon-
sistency using meta-regression with the help of the codes provid-
ed in NICE DSU guidance if we include a sufficient number of trials
(Dias 2012a). We plan to use the following trial-level covariates for
meta-regression.
• Trials at low risk of bias compared to trials at high risk of bias.• Based on the type of hepatorenal syndrome (type I versus type
II).• Based on the aetiology for cirrhosis (e.g. alcohol-related liver
disease, viral liver diseases, autoimmune liver disease).• Based on the interval between the diagnosis of hepatorenal syn-
drome and the start of treatment.• Based on the co-interventions (e.g. both groups received pro-
phylactic antibiotics to decrease the risk of subacute bacterial
peritonitis).• Based on the period of follow-up (short-term: up to three
months; medium term: more than three months to five years;
long-term: more than five years).• Based on the definition used by authors for serious adverse
events and any adverse events (ICH-GCP 1997 versus other def-
initions).
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We will calculate a single common interaction term when applic-
able (Dias 2012a). If the 95% Crls of the interaction term does not
overlap zero, we will consider this statistically significant hetero-
geneity or inconsistency (depending upon the factor being used as
covariate).
Sensitivity analysis
If a trial reports only per-protocol analysis results, we plan to re-
analyse the results using the best-worst-case scenario and worst-
best-case scenario analyses as sensitivity analyses whenever possi-
ble. We will also perform a sensitivity analysis excluding the trials in
which mean or standard deviation, or both were imputed and use
the median standard deviation in the trials to impute missing stan-
dard deviations.
Presentation of results
We will follow the PRISMA for Network Meta-Analyses while report-
ing (Hutton 2015). We will present the effect estimates with 95% CrI
for each pairwise comparison calculated from the direct compar-
isons and network meta-analysis. We will also present the cumula-
tive probability of the treatment ranks (i.e. the probability that the
intervention is within the top two, the probability that the interven-
tion is within the top three, etc.) in graphs (SUCRA) (Salanti 2011).
We will plot the probability that each intervention was best, sec-
ond best, third best, etc. for each of the different outcomes (ranko-
grams), which are generally considered more informative (Salanti
2011; Dias 2012b). We will also provide the CrI of the probabilities in
the ranking probability tables. We will upload all the raw data and
the codes used for analysis in the European Organization for Nu-
clear Research open source database (Zenodo) and provide a link
within the review.
Grading of evidence
We will present 'Summary of findings' tables for all the primary
and secondary outcomes (see Primary outcomes; Secondary out-
comes). We will follow the approach suggested by Puhan and col-
leagues (Puhan 2014). First, we will calculate the direct and indi-
rect effect estimates and 95% CrI using the node-splitting approach
(Dias 2010), that is calculating the direct estimate for each compar-
ison by including only trials in which there was direct comparison
of interventions and the indirect estimate for each comparison by
excluding the trials in which there was direct comparison of inter-
ventions. Next, we will rate the quality of direct and indirect effect
estimates using GRADE methodology, which takes into account the
risk of bias, inconsistency, directness of evidence, imprecision, and
publication bias (Guyatt 2011). We will then present the estimates
of the network meta-analysis and rate the quality of network meta-
analysis effect estimates as the best quality of evidence between
the direct and indirect estimates (Puhan 2014). In addition, we will
present information on the absolute measures (i.e. proportion of
people with the outcome in each intervention group based on the
direct estimates, indirect estimates, and network meta-analysis es-
timates). We will also present information on the number of trials
and participants as per the standard 'Summary of findings' table.
Recommendations for future research
We will also provide recommendations for future research in the
population, intervention, control, outcomes, period of follow-up,
and study design based on the uncertainties that we identify from
the existing research.
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A D D I T I O N A L   T A B L E S
 
• Diagnosis of cirrhosis and ascites• Diagnosis of acute kidney injury (AKI) according to International Club of Ascites AKI criteria (ICA-AKI) criteria*• No response after two consecutive days of diuretic withdrawal and plasma volume expansion with albumin 1 g per kg of body weight• Absence of shock• No current or recent use of nephrotoxic drugs (non-steroidal anti-inflammatory drugs (NSAIDs), aminoglycosides, iodinated contrast
media, etc.)• No macroscopic signs of structural kidney injury, defined as: absence of proteinuria (> 500 mg/day), absence of microhaematuria (>
50 red blood cells per high-power field), and normal findings on renal ultrasonography. Individuals who fulfil these criteria may still
have structural damage such as tubular damage. Urine biomarkers will become an important element in making a more accurate
differential diagnosis between hepatorenal syndrome and acute tubular necrosis.
Table 1.   Criteria for diagnosis of hepatorenal syndrome 
*Increase in serum creatinine ≥ 0.3 mg/dL (≥ 26.5 µmol/L) within 48 hours or ≥ 50% increase in serum creatinine from baseline which is
known or presumed to have occurred within the previous seven days.
Source: Angeli 2015
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Appendix 1. Search strategies
 
Database Time span Search strategy
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Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Central Register of Con-
trolled Trials (CENTRAL) in
the Cochrane Library
Latest issue #1 MeSH descriptor: [Hepatorenal Syndrome] explode all trees
#2 hepatorenal syndrom*
#3 #1 or #2
MEDLINE Ovid January 1947 to
date of search
1. exp Hepatorenal Syndrome/
2. hepatorenal syndrom*.ti,ab.
3. 1 or 2
4. randomized controlled trial.pt.
5. controlled clinical trial.pt.
6. randomized.ab.
7. placebo.ab.
8. drug therapy.fs.
9. randomly.ab.
10. trial.ab.
11. groups.ab.
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. exp animals/ not humans.sh.
14. 12 not 13
15. 3 and 14
Embase Ovid January 1974 to
date of search
1. exp hepatorenal syndrome/
2. hepatorenal syndrom*.ti,ab.
3. 1 or 2
4. exp crossover-procedure/ or exp double-blind procedure/ or exp randomized
controlled trial/ or single-blind procedure/
5. (((((random* or factorial* or crossover* or cross over* or cross-over* or place-
bo* or double*) adj blind*) or single*) adj blind*) or assign* or allocat* or volun-
teer*).af.
6. 4 or 5
7. 3 and 6
Science Citation Index Ex-
panded (Web of Science)
January 1945 to
date of search
#1 TS= (hepatorenal syndrom*)
#2 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR
meta-analysis OR systematic review* OR meta-analys*)
#3 #1 AND #2
World Health Organization
International Clinical Tri-
als Registry Platform (app-
Date of search to
be provided at the
review stage
Condition: hepatorenal syndrome
  (Continued)
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Cochrane Database of Systematic Reviews
s.who.int/trialsearch/De-
fault.aspx)
ClinicalTrials.gov Date of search to
be provided at the
review stage
Interventional Studies | Hepatorenal Syndrome | Phase 2, 3, 4
European Medicines
Agency (www.ema.eu-
ropa.eu/ema/) and US
Food and Drug Adminis-
tration (www.fda.gov)
Date of search to
be provided at the
review stage
Hepatorenal syndrome
  (Continued)
 
Appendix 2. Sample size calculation
Approximately 30% to 60% of people with hepatorenal syndrome die within a year (Israelsen 2017). The required information size based on
a control group proportion of 40%, a relative risk reduction of 20% in the experimental group, type I error of 5%, and type II error of 20% is
1128 participants. Network analyses are more prone to risk of random errors than direct comparisons (Del Re 2013). Accordingly, a greater
sample size is required in indirect comparisons than in direct comparisons (Thorlund 2012). The power and precision in indirect compar-
isons depend upon various factors, such as the number of participants included for each comparison and the heterogeneity between the
trials (Thorlund 2012). If there is no heterogeneity across the trials, the sample size in indirect comparisons would be equivalent to the
sample size in direct comparisons. The effective indirect sample size can be calculated using the number of participants included in each
direct comparison (Thorlund 2012). For example, a sample size of 2500 participants in the direct comparison A versus C (nAC) and a sample
size of 7500 participants in the direct comparison B versus C (nBC) results in an effective indirect sample size of 1876 participants. However,
in the presence of heterogeneity within the comparisons, the required sample size is higher. In the above scenario, for an I2 statistic for
each of the comparisons A versus C (IAC2) and B versus C (IBC2) of 25%, the effective indirect sample size is 1407 participants. For an I2
statistic for each of the comparisons A versus C and B versus C of 50%, the effective indirect sample size is 938 participants (Thorlund 2012).
If there are only three groups, and the sample size in the trials is more than the required information size, we will calculate the effective
indirect sample size using the following generic formula (Thorlund 2012):
(nAC x (1 - IAC2)) x (nBC x (1 - IBC2))/(nAC x (1 - IAC2)) + (nBC x (1 - IBC2)).
Currently, there is no method to calculate the effective indirect sample size for a network analysis involving more than three intervention
groups.
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